Dr. Feng Li
Feng (Frank) Li, Ph.D., is President of Alliance Pharma; he obtained his Ph.D. degree in Bioanalytical Chemistry jointly from Concordia University and the National Institute of Scientific Research (Canadian Doping Control Center) in Montreal, Canada. Subsequently, Dr. Li did his post-doctoral fellowship at the Biomedical Mass Spectrometry Facility at the Mayo Clinic in Rochester, Minnesota. Furthermore, Dr. Li has an M.Sc. degree in Natural Product Chemistry and a B.S. in Pharmacy. He has held leadership roles in the Department of Drug Discovery Metabolism at Phoenix International Life Sciences, Inc., a major CRO at the time in Montreal, Canada, which was later acquired by MDS Pharma Services; in the Drug Analysis group in the Department of Drug Metabolism and Pharmacokinetics (DMPK) at GlaxoSmithKline; and in the Drug Metabolism group in the Department of Drug Safety and Disposition at Cephalon, Inc. Dr. Li has extensive DMPK experience in discovery and developmental phases of drug development. With more than 20 years in the pharmaceutical biotechnology, and CRO industry, he is well versed in bioanalytical techniques for both qualitative (drug metabolite identification) and quantitative (PK/TK) drug analysis and has published numerous articles in the area of drug metabolite identification and quantitation.
Dr. Michael Zhang
Michael Zhang, Ph.D., serves as Vice President of Quality at Alliance Pharma. Prior to his current positon, Dr. Zhang was the Vice President of Operations. Dr. Zhang has extensive experience in Analytical Chemistry, Computer Science, and Quality and Regulatory Compliance. His expertise includes development and validation of LC-MS/MS methods for analyses of biological samples and pesticide/herbicide residue samples, FDA/EPA/OECD GLP compliance, quality management systems, analytical instrumentation, software development, information technology, and computerized systems validation. Before joining Alliance, Dr. Zhang was an Associate Director at Keystone Analytical Laboratories (a subsidiary of former Pharmanet Development Group, Inc.). At several companies, Dr. Zhang has developed numerous challenging LC-MS/MS analytical methods, built up the IT infrastructure, and established 21 CFR Part 11 compliance of computerized systems. Dr. Zhang has also worked as a software engineer at Motorola (Chicago, IL) and a Programmer Analyst at Affina (Peoria, IL). Dr. Zhang earned his Ph.D. degree in Analytical Chemistry and M.Sc. degree in Computer Science, both from the University of Missouri-Rolla (Rolla, MO). Dr. Zhang also holds an M.Sc. degree in Analytical Chemistry and a B.S. degree in Chemistry from the University of Science and Technology of China.
Dr. Masood Khan
Masood Khan, PhD, Vice President of Biopharmaceutical Services, is an internationally renowned thought leader in the field of regulatory compliant ligand-binding assays (LBAs). Dr. Khan brings over 25 years of unparalleled knowledge of immunoanalytical sciences and technologies to head scientific operations and compliance of large molecule bioanalyses at Alliance Pharma. To his credit, Dr. Khan has over 120 publications and presentations, including several white papers and a book entitled, Ligand-Binding Assays: Development, Validation, and Implementation in the Drug Development Arena—a consolidated and comprehensive reference widely used in the pharmaceutical industry. Prior to joining Alliance Pharma, Dr. Khan had served in executive capacities at several major contract research organizations and pharmaceutical companies, including Phoenix International Life Sciences, NeuroBiotech, Medlmmune, Covance, and KCAS. He earned his PhD degree in Biological Sciences from Aligarh University in India, followed by post-doctoral fellowships both at the National Institute of Environmental Health Sciences (NIEH) in North Carolina and at McGill University in Montreal. Dr. Khan is a founding member of the Ligand-Binding Assay Bioanalytical Focus Group (LBABFG) at the American Association of Pharmaceutical Scientists (AAPS). He has long been a contributing member at the AAPS, chairing and leading discussions on large molecule bioanalysis. In recent years, he has served on several AAPS subcommittees geared toward formulating recommendations related to singleplex and multiplex biomarker assay validation, biomarker sample stability considerations, and creation of pharmaceutical grade kits for biomarker quantification. He is recipient of 2016 AAPS Biotechnology section Distinguished Service Award.
Dr. Zhiyang Zhao
Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) of Alliance Pharma. Dr. Zhao has over 20 years of pharmaceutical industry experience with special focus on metabolic and pharmacokinetic properties of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. For the past 11 years, Dr. Zhao served as Site Director for Preclinical Studies at Amgen in Cambridge, Massachusetts. Dr. Zhao’s extensive experience spans the entire drug discovery and development process (discovery, development, and in-/out-licensing) in oncology, metabolic, antiviral, CNS, and inflammatory diseases. Dr. Zhao’s contributions and accomplishments of integrating in vitro and in vivo ADMET (absorption, distribution, metabolism, excretion, and toxicity) information to optimize drug candidate properties are documented in over 50 peer‑reviewed scientific publications and 4 patents in the areas of new drug targets, drug metabolism, pharmacokinetics, and toxicology. Currently, Dr. Zhao also holds an appointment as Adjunct Professor at the Eshelman School of Pharmacy at the University of North Carolina at Chapel Hill, North Carolina, and serves as Editor-in-Chief of Drug Metabolism Letters, a journal by Bentham Science, which publishes short papers on major advances in all areas of drug metabolism and disposition. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.
Song Lin, M.Sc., Director of Drug Metabolism and Pharmacokinetics, has been with Alliance Pharma since 2012. In this role, he closely works with biotechnology and pharmaceutical companies to build strategic outsourcing partnerships for discovery preclinical services, regulated bioanalysis for submissions, and clinical development projects. Prior to joining Alliance, Mr. Lin worked as the head of Drug Metabolism Laboratories at Novartis Institutes of Biomedical Research in Emeryville, California He has also held roles at Chiron Corporation, COR Therapeutics Inc., Covance Laboratories, and Phoenix International Life Sciences, Inc. Mr. Lin received his M.Sc. degree in Biology and Plant Anatomy at the Sun Yatsen University in Guangzhou, China. He subsequently earned his second M.Sc. degree in Biochemistry at the University of Alberta, in Edmonton, Canada. Notably, Mr. Lin has presented at NIH, Novartis Global Discovery Chemistry Congress, and the Society of Toxicology Annual meetings. His most recent publication entitled, “3D Pharmacophore Model-Assisted Discovery of Novel CDC7 Inhibitors” was published in 2011 in ACS Medicinal Chemistry Letters.
Dr. Colin Barry
Colin Barry, Ph.D., who leads the Bioanalysis department, brings more than a decade of experience in LC-MS analysis of proteins and peptides. Prior to joining Alliance, Dr. Barry led the Biologics group at SGS, a multinational CRO headquartered in Switzerland. Dr. Barry has also worked for the U.S. Food and Drug Administration (FDA) performing applied research and method development for the analysis and characterization of biopharmaceuticals. While at the FDA, Dr. Barry was awarded the Commissioner’s Special Citation for his work with the Necrotizing Enterocolitis Response Group. Dr. Barry earned his doctorate degree in Chemistry from Wake Forest University in Winston-Salem, North Carolina. Subsequently, he did a postdoctoral fellowship at the University of Pennsylvania Perelman School of Medicine Center for Cancer Pharmacology in the laboratory of Dr. Ian Blair. Dr. Barry’s research has been published in multiple scientific journals including Blood, Journal of Proteome Research, and the Journal of the American Chemical Society. In addition, he is an active member of the American Chemical Society and the American Society for Mass Spectrometry. In 2014, Dr. Barry was admitted to the U.S. Patent Bar.
Dr. Deping Cheng
Deping Cheng, Ph.D. serves as Director of Bioanalysis at Alliance Pharma. He has more than 15 years of experience in the CRO and large pharmaceutical companies collaborating on global cross-company and integrated inter-company outsourcing and collaborative global projects. He has extensive experience in working with CRO organizations in evaluating, training, mentoring, monitoring bioanalytical and pharmacological method development and data interpretation of their operations from a scientific perspective. During his 10-year tenure at Johnson & Johnson, Dr. Cheng has played a significant role in the discovery and development of 7 marketed products in several therapeutic areas, such as SGLT1/2 inhibitor drug of Canagliflozin. In addition, during his work at J&J, he has been involved in several dozen projects during the lead discovery, lead optimization, and early development stages. Dr. Cheng earned his Ph.D., M.S., and B.S. degrees in Analytical Chemistry from Zhejiang University in China. Following the completion of his doctorate degree, Dr. Cheng completed three successive post-doctoral appointments at San Francisco State University, the University of Oklahoma, and concurrently at both The Ohio State University College of Pharmacy and The Ohio State University Comprehensive Cancer Center. During his post-doctoral work, Dr. Cheng provided bioanalysis, drug metabolism, and pharmacokinetic support for preclinical and clinical studies in the areas of oncology and HIV.
Dr. Weiqing Chen
Weiqing Chen, Ph.D., Director of Drug Metabolism, earned his doctorate degree in Biology from the University of Kansas in Lawrence, Kansas. Dr. Chen brings more than 14 years of research and industry experience in drug discovery and development. He established DMPK service capability at a leading CRO in China. While there, he developed stable business relationships with more than 100 clients in the U.S., Europe, Japan, and China. He led the DMPK effort in numerous integrated drug discovery and development programs. He also made significant contributions in designing and managing preclinical DMPK studies for regulatory filings in the U.S. and China. Dr. Chen is an expert in designing and conducting ADME studies as well as LC-MS/MS method development and sample analysis.